Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

Table 1

Current HCV NS3-4A protease inhibitors/drugs in pipeline (/r means boosted by ritonavir).

Mechanism	Inhibitor name	Genotypic coverage	Daily dosing	Company	Status
Reversible covalent inhibitor	Incivek (telaprevir, VX-950)	1	Three times	Vertex	Approved
	Victrelis (boceprevir, SCH503034)	1	Three times	Merck	Approved
Noncovalent inhibitor	ABT-450/r	1	Once	Abbott	Phase III
	Simeprevir (TMC435)	1, 2, 5, and 6	Once	Janssen	Phase III
	Faldaprevir (BI201335)	1	Once	Boehringer Ingelheim	Phase III
	Danoprevir (RG7227)	1	Twice	Genentech	Phase II
	Vaniprevir (MK-7009)	1	Twice	Merck	Phase II
	MK-5172	1, 2	Once	Merck	Phase II
	Asunaprevir (BMS-650032)	1, 4	Once	Bristol-Myers Squibb	Phase II
	ACH-1625	1	Once	Achillion	Phase II
	GS-9256	1	Twice	Gilead	Phase II
	ACH-2684	1, 3	Once	Achillion	Phase II
	GS-9451	1a, 1b	Once	Gilead	Phase II
	Narlaprevir/r	1	Once	Merck	Phase II
	IDX320	1, 1b, 3a, and 4a	Once	Idenix	Phase II